
Editor’s Choice

Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview
First described in the 4th Century in China, practiced since the 1950’s and re-discovered relatively recently [1][2], Fecal Microbiota Transplantation (FMT) or simply Fecal Transplant is a therapeutic approach in which more or less processed […]

Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers

Did you miss Probiota Copenhagen 2022? Catch up now!
With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]
In Case you Missed it:

Enterome signs major strategic R&D collaboration with Nestlé Health Science
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its highly productive bacterial Mimicry drug discovery platform, today announces that it has signed a strategic R&D collaboration and license agreement with Nestlé […]

Seed Health and Axial Therapeutics Launch Gut-Brain Development Program
Seed Health, a microbiome science company, and Axial Therapeutics, a clinical-stage biopharmaceutical company, today announced a joint development program targeting the microbiome-gut-brain axis for mental health, with the potential to impact well-being in areas like […]

Researchers propose widespread banking of stool samples for fecal transplants later in life
Changes in the way that humans live and eat have resulted in tremendous alterations in the gut microbiome, especially over the past few decades. These changes have been linked to increased rates of asthma, allergies, […]

What to consider before launching a Direct-to-Consumer Microbiome Test
For US writer Michael Pollan, viewing the results of his first microbiome test was a pivotal moment. In a 2013 article for The New York Times Magazine, Pollan recalled that the moment he opened the […]

Boehringer Ingelheim and BiomX Collaborate to Discover IBD Microbiome Biomarkers
BiomX Inc. (NYSE American: PHGE) (“BiomX” or “Company”) announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (“IBD”). BiomX is a clinical-stage microbiome company advancing novel natural and engineered phage […]

4D pharma Receives Notice of Delisting From Nasdaq
Source: 4D Pharma 4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announced that on June 27, 2022, it received written […]

Vedanta Unveils State-of-the-Art Manufacturing Facility
Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, announced the opening of a new facility designed to manufacture clinical and commercial supply for its therapeutic portfolio, […]

Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview
First described in the 4th Century in China, practiced since the 1950’s and re-discovered relatively recently [1][2], Fecal Microbiota Transplantation (FMT) or simply Fecal Transplant is a therapeutic approach in which more or less processed […]